Is Senti Biosciences Stock a Good Investment?
Senti Biosciences Investment Advice | SNTI |
- Examine Senti Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Senti Biosciences' leadership team and their track record. Good management can help Senti Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Senti Biosciences' business and its evolving consumer preferences.
- Compare Senti Biosciences' performance and market position to its competitors. Analyze how Senti Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Senti Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Senti Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Senti Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Senti Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Senti Biosciences Stock
Researching Senti Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.62. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Senti Biosciences recorded a loss per share of 15.59. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 18th of July 2024.
To determine if Senti Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Senti Biosciences' research are outlined below:
| Senti Biosciences generated a negative expected return over the last 90 days | |
| Senti Biosciences has high historical volatility and very poor performance | |
| Senti Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (71.06 M) with loss before overhead, payroll, taxes, and interest of (29.78 M). | |
| Senti Biosciences currently holds about 140.78 M in cash with (52.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Senti Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com |
Senti Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Senti Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Senti Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Senti Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Senti Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-11 | 2023-06-30 | -0.48 | -0.42 | 0.06 | 12 | ||
2022-11-10 | 2022-09-30 | -0.46 | -0.38 | 0.08 | 17 | ||
2024-03-21 | 2023-12-31 | -0.23 | -0.4191 | -0.1891 | 82 | ||
2023-11-13 | 2023-09-30 | -0.44 | 0.24 | 0.68 | 154 |
Know Senti Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Senti Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Senti Biosciences backward and forwards among themselves. Senti Biosciences' institutional investor refers to the entity that pools money to purchase Senti Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-06-30 | 0.0 | 8vc Gp I Llc | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Ark Investment Management Llc | 2024-09-30 | 176.7 K | Vanguard Group Inc | 2024-09-30 | 97.5 K | Geode Capital Management, Llc | 2024-09-30 | 27.3 K | Harbour Investments, Inc. | 2024-09-30 | 1.5 K | Citigroup Inc | 2024-09-30 | 166 | Wells Fargo & Co | 2024-06-30 | 0.0 | Comerica Bank | 2024-06-30 | 0.0 | The Toronto-dominion Bank | 2024-06-30 | 0.0 |
Senti Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.91 M.Market Cap |
|
Senti Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.39) | (1.32) |
Determining Senti Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Senti Biosciences is a good buy. For example, gross profit margin measures Senti Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Senti Biosciences' profitability and make more informed investment decisions.
Evaluate Senti Biosciences' management efficiency
Senti Biosciences has return on total asset (ROA) of (0.3302) % which means that it has lost $0.3302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1107) %, meaning that it created substantial loss on money invested by shareholders. Senti Biosciences' management efficiency ratios could be used to measure how well Senti Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.82. The current Return On Capital Employed is estimated to decrease to -0.91. As of now, Senti Biosciences' Net Tangible Assets are increasing as compared to previous years. The Senti Biosciences' current Non Currrent Assets Other is estimated to increase to about 2.1 M, while Total Assets are projected to decrease to under 105.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 15.08 | 15.83 | |
| Tangible Book Value Per Share | 15.08 | 15.83 | |
| Enterprise Value Over EBITDA | (0.51) | (0.53) | |
| Price Book Value Ratio | 0.44 | 0.42 | |
| Enterprise Value Multiple | (0.51) | (0.53) | |
| Price Fair Value | 0.44 | 0.42 | |
| Enterprise Value | 31 M | 29.5 M |
Understanding the operational decisions made by Senti Biosciences management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 2.746 |
Basic technical analysis of Senti Stock
As of the 1st of December, Senti Biosciences has the Variance of 20.51, coefficient of variation of (2,792), and Risk Adjusted Performance of (0.02). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Senti Biosciences, as well as the relationship between them.Senti Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Senti Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Senti Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Senti Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Senti Biosciences' Outstanding Corporate Bonds
Senti Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Senti Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Senti bonds can be classified according to their maturity, which is the date when Senti Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| SENMED 2927 01 NOV 51 Corp BondUS81728XAA63 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ST 5875 01 SEP 30 Corp BondUS81725WAL72 | View | |
| US81725WAK99 Corp BondUS81725WAK99 | View | |
| SENIOR HSG PPTYS Corp BondUS81721MAM10 | View |
Understand Senti Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Senti Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (2.48) | |||
| Mean Deviation | 3.12 | |||
| Coefficient Of Variation | (2,792) | |||
| Standard Deviation | 4.53 | |||
| Variance | 20.51 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.93) | |||
| Treynor Ratio | (2.49) | |||
| Maximum Drawdown | 29.17 | |||
| Value At Risk | (7.36) | |||
| Potential Upside | 7.04 | |||
| Skewness | (1.48) | |||
| Kurtosis | 6.57 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (2.48) | |||
| Mean Deviation | 3.12 | |||
| Coefficient Of Variation | (2,792) | |||
| Standard Deviation | 4.53 | |||
| Variance | 20.51 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.93) | |||
| Treynor Ratio | (2.49) | |||
| Maximum Drawdown | 29.17 | |||
| Value At Risk | (7.36) | |||
| Potential Upside | 7.04 | |||
| Skewness | (1.48) | |||
| Kurtosis | 6.57 |
Consider Senti Biosciences' intraday indicators
Senti Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Senti Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Senti Biosciences Corporate Filings
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 29th of May 2024 Other Reports | ViewVerify |
Senti Stock media impact
Far too much social signal, news, headlines, and media speculation about Senti Biosciences that are available to investors today. That information is available publicly through Senti media outlets and privately through word of mouth or via Senti internal channels. However, regardless of the origin, that massive amount of Senti data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Senti Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Senti Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Senti Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Senti Biosciences alpha.
Senti Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Senti Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Senti Biosciences Corporate Management
| Dee Dragon | Vice Culture | Profile | |
| Thomas Chung | Vice Development | Profile | |
| Susan Kahlert | Controller | Profile | |
| James Collins | Chairperson CoFounder | Profile | |
| Wilson Wong | Scientific Board | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.59) | Revenue Per Share 0.075 | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (1.11) |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Senti Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.